Therapeutic drug monitoring (TDM) plays a critical role in maximizing the benefits of biologic and biosimilar therapy for the treatment of inflammatory bowel disease (IBD). TDM involves measuring blood drug concentrations and detecting anti-drug antibodies (ADAs) to ensure the effectiveness of the therapy and make necessary adjustments when required. In this webinar, Dr. Michael J Rosen, pediatric gastroenterologist from Stanford University, provides an update on TDM for IBD and discusses the strengths and limitations of therapeutic drug monitoring for IBD.
Michael J Rosen, MD, MSCI
Stanford University Endowed Professor for Pediatric IBD and Celiac disease
Director, Center for Pediatric IBD and Celiac Disease
To view this webinar, please complete the following form.
2024 EUROIMMUN US
